跳至主要内容
临床试验/CTRI/2023/12/060521
CTRI/2023/12/060521尚未招募Unknown

A pilot study evaluating the feasibility of BCAL’s blood-based lipidomic biomarker signature for breast cancer detection in women. - BCAL-PRO-08

BCAL Diagnostics Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
Unknown
状态
尚未招募

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • Able and willing to provide informed consent
  • Women assigned female at birth (AFAB)
  • Aged 30 years or older
  • Treatment naïve
  • Not on any hormone replacement therapy
  • Diagnosed with primary breast cancer, with no previous history of known cancer OR recently confirmed (radiological/pathological) benign breast lump with no previous history of known cancer OR no current or previous history of known cancer.

排除标准

  • Pregnant or breast feeding
  • Any acute or chronic condition that would limit the ability of the patient to participate in the study
  • Previous (or current) chemotherapy or radiotherapy treatment
  • Currently on hormone replacement therapy
  • Refusal to provide informed consent
  • Previous history of cancer

研究者

相似试验

Blood-based lipidomic biomarker signature for breast... | 临床试验